Sytze de Roock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sytze de Roock has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Marc H. A. Jansen
Department of Paediatric Immunology & Rheumatology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Lundlaan 6, Utrecht, The Netherlands
2 shared publications- Marianne Boes
Center for Translational Immunology, University Medical Centre Utrecht, Utrecht, Netherlands
2 shared publications Rianne Scholman
Paediatric Immunology, Laboratory of Translational Immunology LTI, University Medical Center Utrecht, Utrecht, The Netherlands
2 shared publicationsSebastiaan J. Vastert
Department of Paediatric Immunology & Rheumatology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Lundlaan 6, Utrecht, The Netherlands
2 shared publications- Sebastiaan J. Vastert
Center for Translational Immunology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands
2 shared publications - Agnes Szentpetery
UCD Conway Institute of Biomolecular and Biomedical Research, School of Medicine, University College Dublin, Ireland.
1 shared publication
Latest Publications
- Open Access
- 24 April 2026
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 24 (1)
Morning stiffness duration is associated with physician active joint count in juvenile idiopathic arthritis
The aim of this study was to assess whether there is an association between morning stiffness duration and the presence of active arthritis in children with Juvenile Idiopathic Arthritis (JIA). A single-center retrospective observational study was conducted using data from the Wilhelmina Children’s Hospital. Morning stiffness duration was obtained through Juvenile Arthritis Multidimensional Assessment Report (JAMAR) questionnaires completed by patients around the time of their visit to the paediatric rheumatology clinic. Active arthritis was characterized by using the Active Joint Count (AJC) indicated by the pediatric rheumatologist and was defined as an AJC ≥ 1. Associations between morning stiffness and disease activity were investigated with Kruskal-Wallis and Chi-squared tests. A total of 5421 JAMAR questionnaires from 803 JIA patients who visited the hospital between December 2012 and August 2024 were analysed in this study. A statistically significant association (p < 0.001) was found between morning stiffness duration and the AJC. A diagnostic model with different cut-off values of morning stiffness to predict the presence of active arthritis was constructed, and showed a sensitivity ranging from 0.545 − 0.062 and specificity ranging from 0.755 to 0.990. Our findings show the association between active arthritis and the duration of morning stiffness in JIA patients. The association between morning stiffness and active arthritis could potentially be of value in a multivariate model for monitoring patients remotely and determining whether patients need to be assessed by their physician earlier. The online version contains supplementary material available at 10.1186/s12969-026-01210-x.
- 24 April 2026
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 24 (1)
Open AccessMorning stiffness duration is associated with physician active joint count in juvenile idiopathic arthritis
The aim of this study was to assess whether there is an association between morning stiffness duration and the presence of active arthritis in children with Juvenile Idiopathic Arthritis (JIA). A single-center retrospective observational study was conducted using data from the Wilhelmina Children’s Hospital. Morning stiffness duration was obtained through Juvenile Arthritis Multidimensional Assessment Report (JAMAR) questionnaires completed by patients around the time of their visit to the paediatric rheumatology clinic. Active arthritis was characterized by using the Active Joint Count (AJC) indicated by the pediatric rheumatologist and was defined as an AJC ≥ 1. Associations between morning stiffness and disease activity were investigated with Kruskal-Wallis and Chi-squared tests. A total of 5421 JAMAR questionnaires from 803 JIA patients who visited the hospital between December 2012 and August 2024 were analysed in this study. A statistically significant association (p < 0.001) was found between morning stiffness duration and the AJC. A diagnostic model with different cut-off values of morning stiffness to predict the presence of active arthritis was constructed, and showed a sensitivity ranging from 0.545 − 0.062 and specificity ranging from 0.755 to 0.990. Our findings show the association between active arthritis and the duration of morning stiffness in JIA patients. The association between morning stiffness and active arthritis could potentially be of value in a multivariate model for monitoring patients remotely and determining whether patients need to be assessed by their physician earlier. The online version contains supplementary material available at 10.1186/s12969-026-01210-x.
- Open Access
- 29 December 2025
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 23 (1) , 124
Adoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice
The recent development of biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) have expanded the possibiliti
- 29 December 2025
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 23 (1) , 124
Open AccessAdoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice
The recent development of biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) have expanded the possibiliti
- Open Access
Identification and Evaluation of Serum Protein Biomarkers Which Differentiate Psoriatic from Rheumatoid Arthritis
Objectives: To identify serum protein biomarkers which might separate early inflammatory arthritis (EIA) patients with psoriatic arthritis (PsA) from those with rheumatoid arthritis (RA) to provide an accurate diagnosis and support appropriate early intervention. Methods: In an initial protein discovery phase, the serum proteome of a cohort of patients with PsA and RA was interrogated using unbiased liquid chromatography mass spectrometry (LC-MS/MS) (n=64 patients), a multiplexed antibody assay (Luminex) for 48 proteins (n=64 patients) and an aptamer-based assay (SOMAscan) targeting 1,129 proteins (n=36 patients). Subsequently, analytically validated targeted multiple reaction monitoring (MRM) assays were developed to further evaluate those proteins identified as discriminatory during the discovery. During an initial verification phase, MRM assays were developed to a panel of 150 proteins (by measuring a total of 233 peptides) and used to re-evaluate the discovery cohort (n=60). During a second verification phase, the panel of proteins was expanded to include an additional 23 proteins identified in other proteomic discovery analyses of arthritis patients. The expanded panel was evaluated using a second, independent cohort of PsA and RA patients (n=167). Results: Multivariate analysis of the protein discovery data revealed that it was possible to discriminate PsA from RA patients with an area under the curve (AUC) of 0.94 for nLC-MS/MS, 0.69 for Luminex based measurements; 0.73 for SOMAscan analysis. During the initial verification phase, random forest models confirmed that proteins measured by MRM could differentiate PsA and RA patients with an AUC of 0.79 and during the second phase of verification the expanded panel could segregate the two disease groups with an AUC of 0.85. Conclusion: We report a serum protein biomarker panel which can separate EIA patients with PsA from those with RA. We suggest that the routine use of such a panel in EIA patients will improve clinical decision making and with continued evaluation and refinement using additional patient cohorts will support the development of a diagnostic test for patients with PsA.
Open AccessIdentification and Evaluation of Serum Protein Biomarkers Which Differentiate Psoriatic from Rheumatoid Arthritis
Objectives: To identify serum protein biomarkers which might separate early inflammatory arthritis (EIA) patients with psoriatic arthritis (PsA) from those with rheumatoid arthritis (RA) to provide an accurate diagnosis and support appropriate early intervention. Methods: In an initial protein discovery phase, the serum proteome of a cohort of patients with PsA and RA was interrogated using unbiased liquid chromatography mass spectrometry (LC-MS/MS) (n=64 patients), a multiplexed antibody assay (Luminex) for 48 proteins (n=64 patients) and an aptamer-based assay (SOMAscan) targeting 1,129 proteins (n=36 patients). Subsequently, analytically validated targeted multiple reaction monitoring (MRM) assays were developed to further evaluate those proteins identified as discriminatory during the discovery. During an initial verification phase, MRM assays were developed to a panel of 150 proteins (by measuring a total of 233 peptides) and used to re-evaluate the discovery cohort (n=60). During a second verification phase, the panel of proteins was expanded to include an additional 23 proteins identified in other proteomic discovery analyses of arthritis patients. The expanded panel was evaluated using a second, independent cohort of PsA and RA patients (n=167). Results: Multivariate analysis of the protein discovery data revealed that it was possible to discriminate PsA from RA patients with an area under the curve (AUC) of 0.94 for nLC-MS/MS, 0.69 for Luminex based measurements; 0.73 for SOMAscan analysis. During the initial verification phase, random forest models confirmed that proteins measured by MRM could differentiate PsA and RA patients with an AUC of 0.79 and during the second phase of verification the expanded panel could segregate the two disease groups with an AUC of 0.85. Conclusion: We report a serum protein biomarker panel which can separate EIA patients with PsA from those with RA. We suggest that the routine use of such a panel in EIA patients will improve clinical decision making and with continued evaluation and refinement using additional patient cohorts will support the development of a diagnostic test for patients with PsA.
- Open Access
Dysregulated RASGRP1 expression through RUNX1 mediated transcription promotes autoimmunity
RasGRP1 is a Ras guanine nucleotide exchange factor, and an essential regulator of lymphocyte receptor signaling. In mice, Rasgrp1 deletion results in defective T lymphocyte development. RASGRP1 -deficient patients suffer from immune deficiency, and the RASGRP1 gene has been linked to autoimmunity. However, how RasGRP1 levels are regulated, and if RasGRP1 dosage alterations contribute to autoimmunity remains unknown. We demonstrate that diminished Rasgrp1 expression caused defective T lymphocyte selection in C57BL/6 mice, and that the severity of inflammatory disease inversely correlates with Rasgrp1 expression levels. In patients with autoimmunity, active inflammation correlated with decreased RASGRP1 levels in CD4 + T cells. By analyzing H3K27 acetylation profiles in human T cells, we identified a RASGRP1 enhancer that harbors autoimmunity-associated SNPs. CRISPR-Cas9 disruption of this enhancer caused lower RasGRP1 expression, and decreased binding of RUNX1 and CBFB transcription factors. Analyzing patients with autoimmunity, we detected reduced RUNX1 expression in CD4 + T cells. Lastly, we mechanistically link RUNX1 to transcriptional regulation of RASGRP1 to reveal a key circuit regulating RasGRP1 expression, which is vital to prevent inflammatory disease.
Open AccessDysregulated RASGRP1 expression through RUNX1 mediated transcription promotes autoimmunity
RasGRP1 is a Ras guanine nucleotide exchange factor, and an essential regulator of lymphocyte receptor signaling. In mice, Rasgrp1 deletion results in defective T lymphocyte development. RASGRP1 -deficient patients suffer from immune deficiency, and the RASGRP1 gene has been linked to autoimmunity. However, how RasGRP1 levels are regulated, and if RasGRP1 dosage alterations contribute to autoimmunity remains unknown. We demonstrate that diminished Rasgrp1 expression caused defective T lymphocyte selection in C57BL/6 mice, and that the severity of inflammatory disease inversely correlates with Rasgrp1 expression levels. In patients with autoimmunity, active inflammation correlated with decreased RASGRP1 levels in CD4 + T cells. By analyzing H3K27 acetylation profiles in human T cells, we identified a RASGRP1 enhancer that harbors autoimmunity-associated SNPs. CRISPR-Cas9 disruption of this enhancer caused lower RasGRP1 expression, and decreased binding of RUNX1 and CBFB transcription factors. Analyzing patients with autoimmunity, we detected reduced RUNX1 expression in CD4 + T cells. Lastly, we mechanistically link RUNX1 to transcriptional regulation of RASGRP1 to reveal a key circuit regulating RasGRP1 expression, which is vital to prevent inflammatory disease.
- Open Access
- 8 January 2019
- Published by MDPI AG in Pharmaceuticals
- Vol. 12 (1) , 9
Juvenile Arthritis Patients Suffering from Chronic Inflammation Have Increased Activity of Both IDO and GTP-CH1 Pathways But Decreased BH4 Efficacy: Implications for Well-Being, Including Fatigue, Cognitive Impairment, Anxiety, and Depression
Juvenile idiopathic arthritis (JIA) represents joint inflammation with an unknown cause that starts before the age of 16, resulting in stiff and painful joints. In addition, JIA patients often report symptoms of sickness behavior. Recent animal studies suggest that proinflammatory cytokines produce sickness behavior by increasing the activity of indoleamine-2,3-dioxygenase (IDO) and guanosinetriphosphate–cyclohydrolase-1 (GTP–CH1). Here, it is hypothesized that inflammation in JIA patients enhances the enzymatic activity of IDO and GTP-CH1 and decreases the co-factor tetrahydrobiopterin (BH4). These compounds play a crucial role in the synthesis and metabolism of neurotransmitters. The aim of our study was to reveal whether inflammation affects both the GTP-CH1 and IDO pathway in JIA patients. Serum samples were collected from twenty-four JIA patients. In these samples, the concentrations of tryptophan (TRP), kynurenine (KYN), tyrosine (TYR), neopterin, and phenylalanine (PHE) were measured. An HPLC method with electrochemical detection was developed to quantify tryptophan, kynurenine, and tyrosine. Neopterin and phenylalanine were quantified by ELISA. The KYN/TRP ratio was measured as an index of IDO activity, while the PHE/TYR ratio was measured as an index of BH4 activity. Neopterin concentrations were used as an indirect measure of GTP-CH1 activity. JIA patients with high disease activity showed higher levels of both neopterin and kynurenine, and a higher ratio of both KYN/TRP and PHE/TYR and lower tryptophan levels than clinically inactive patients. Altogether, these data support our hypothesis that inflammation increases the enzymatic activity of both IDO and GTP-CH1 but decreases the efficacy of the co-factor BH4. In the future, animal studies are needed to investigate whether inflammation-induced changes in these enzymatic pathways and co-factor BH4 lower the levels of the brain neurotransmitters glutamate, noradrenaline, dopamine, serotonin, and melatonin, and consequently, whether they may affect fatigue, cognition, anxiety, and depression. Understanding of these complex neuroimmune interactions provides new possibilities for Pharma-Food interventions to improve the quality of life of patients suffering from chronic inflammation.
- 8 January 2019
- Published by MDPI AG in Pharmaceuticals
- Vol. 12 (1) , 9
Open AccessJuvenile Arthritis Patients Suffering from Chronic Inflammation Have Increased Activity of Both IDO and GTP-CH1 Pathways But Decreased BH4 Efficacy: Implications for Well-Being, Including Fatigue, Cognitive Impairment, Anxiety, and Depression
Juvenile idiopathic arthritis (JIA) represents joint inflammation with an unknown cause that starts before the age of 16, resulting in stiff and painful joints. In addition, JIA patients often report symptoms of sickness behavior. Recent animal studies suggest that proinflammatory cytokines produce sickness behavior by increasing the activity of indoleamine-2,3-dioxygenase (IDO) and guanosinetriphosphate–cyclohydrolase-1 (GTP–CH1). Here, it is hypothesized that inflammation in JIA patients enhances the enzymatic activity of IDO and GTP-CH1 and decreases the co-factor tetrahydrobiopterin (BH4). These compounds play a crucial role in the synthesis and metabolism of neurotransmitters. The aim of our study was to reveal whether inflammation affects both the GTP-CH1 and IDO pathway in JIA patients. Serum samples were collected from twenty-four JIA patients. In these samples, the concentrations of tryptophan (TRP), kynurenine (KYN), tyrosine (TYR), neopterin, and phenylalanine (PHE) were measured. An HPLC method with electrochemical detection was developed to quantify tryptophan, kynurenine, and tyrosine. Neopterin and phenylalanine were quantified by ELISA. The KYN/TRP ratio was measured as an index of IDO activity, while the PHE/TYR ratio was measured as an index of BH4 activity. Neopterin concentrations were used as an indirect measure of GTP-CH1 activity. JIA patients with high disease activity showed higher levels of both neopterin and kynurenine, and a higher ratio of both KYN/TRP and PHE/TYR and lower tryptophan levels than clinically inactive patients. Altogether, these data support our hypothesis that inflammation increases the enzymatic activity of both IDO and GTP-CH1 but decreases the efficacy of the co-factor BH4. In the future, animal studies are needed to investigate whether inflammation-induced changes in these enzymatic pathways and co-factor BH4 lower the levels of the brain neurotransmitters glutamate, noradrenaline, dopamine, serotonin, and melatonin, and consequently, whether they may affect fatigue, cognition, anxiety, and depression. Understanding of these complex neuroimmune interactions provides new possibilities for Pharma-Food interventions to improve the quality of life of patients suffering from chronic inflammation.
- Open Access
- 20 September 2016
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 14 (1) , 55
The human microbiome and juvenile idiopathic arthritis
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood. The pathogenesis of JIA is thought to be the result of a combination of host genetic and environmental triggers. However, the precise factors that determine one’s susceptibility to JIA remain to be unravelled. The microbiome has received increasing attention as a potential contributing factor to the development of a wide array of immune-mediated diseases, including inflammatory bowel disease, type 1 diabetes and rheumatoid arthritis. Also in JIA, there is accumulating evidence that the composition of the microbiome is different from healthy individuals. A growing body of evidence indeed suggests that, among others, the microbiome may influence the development of the immune system, the integrity of the intestinal mucosal barrier, and the differentiation of T cell subsets. In turn, this might lead to dysregulation of the immune system, thereby possibly playing a role in the development of JIA. The potential to manipulate the microbiome, for example by faecal microbial transplantation, might then offer perspectives for future therapeutic interventions. Before we can think of such interventions, we need to first obtain a deeper understanding of the cause and effect relationship between JIA and the microbiome. In this review, we discuss the existing evidence for the involvement of the microbiome in JIA pathogenesis and explore the potential mechanisms through which the microbiome may influence the development of autoimmunity in general and JIA specifically.
- 20 September 2016
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 14 (1) , 55
Open AccessThe human microbiome and juvenile idiopathic arthritis
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood. The pathogenesis of JIA is thought to be the result of a combination of host genetic and environmental triggers. However, the precise factors that determine one’s susceptibility to JIA remain to be unravelled. The microbiome has received increasing attention as a potential contributing factor to the development of a wide array of immune-mediated diseases, including inflammatory bowel disease, type 1 diabetes and rheumatoid arthritis. Also in JIA, there is accumulating evidence that the composition of the microbiome is different from healthy individuals. A growing body of evidence indeed suggests that, among others, the microbiome may influence the development of the immune system, the integrity of the intestinal mucosal barrier, and the differentiation of T cell subsets. In turn, this might lead to dysregulation of the immune system, thereby possibly playing a role in the development of JIA. The potential to manipulate the microbiome, for example by faecal microbial transplantation, might then offer perspectives for future therapeutic interventions. Before we can think of such interventions, we need to first obtain a deeper understanding of the cause and effect relationship between JIA and the microbiome. In this review, we discuss the existing evidence for the involvement of the microbiome in JIA pathogenesis and explore the potential mechanisms through which the microbiome may influence the development of autoimmunity in general and JIA specifically.
- Open Access
- 30 July 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (24) , 20037-20042
A novel human STAT3 mutation presents with autoimmunity involving Th17 hyperactivation
A novel human STAT3 mutation presents with autoimmunity involving Th17 hyperactivation
- 30 July 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (24) , 20037-20042
Open AccessA novel human STAT3 mutation presents with autoimmunity involving Th17 hyperactivation
A novel human STAT3 mutation presents with autoimmunity involving Th17 hyperactivation
- 1 September 2013
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 132 (3) , 754-756.e3
Defective TH17 development in human neonatal T cells involves reduced RORC2 mRNA content
- 1 September 2013
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 132 (3) , 754-756.e3
Defective TH17 development in human neonatal T cells involves reduced RORC2 mRNA content
- Open Access
- 1 January 2013
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 15 (3) , 213
What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?
This review summarizes the immunological consequences of biological therapies used in juvenile idiopathic arthritis (JIA). For every frequently used biological agent the characteristics are clearly specified (molecular target, isotype, registered indication for JIA, route of administration, half-life, contraindication, very common side effects, expected time of response and average cost in the first year). The emphasis of this review is on the immunological side effects that have been encountered for every separate agent in JIA populations. For each agent these adverse events have been calculated as incidence per 100 patient-years for the following categories: serious infections, tuberculosis, malignancies, response to vaccination, new-onset autoimmune diseases and development of anti-drug antibodies. There are large differences in side effects between various agents and there is a clear need for an international and standardized collection of post-marketing surveillance data of biologicals in the vulnerable group of JIA patients. Such an international pharmacovigilance database, called Pharmachild, has now been started.
- 1 January 2013
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 15 (3) , 213
Open AccessWhat are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?
This review summarizes the immunological consequences of biological therapies used in juvenile idiopathic arthritis (JIA). For every frequently used biological agent the characteristics are clearly specified (molecular target, isotype, registered indication for JIA, route of administration, half-life, contraindication, very common side effects, expected time of response and average cost in the first year). The emphasis of this review is on the immunological side effects that have been encountered for every separate agent in JIA populations. For each agent these adverse events have been calculated as incidence per 100 patient-years for the following categories: serious infections, tuberculosis, malignancies, response to vaccination, new-onset autoimmune diseases and development of anti-drug antibodies. There are large differences in side effects between various agents and there is a clear need for an international and standardized collection of post-marketing surveillance data of biologicals in the vulnerable group of JIA patients. Such an international pharmacovigilance database, called Pharmachild, has now been started.
- 1 December 2011
- Published by Elsevier in Clinical Nutrition
- Vol. 30 (6) , 845-851
Gut derived lactic acid bacteria induce strain specific CD4+ T cell responses in human PBMC
- 1 December 2011
- Published by Elsevier in Clinical Nutrition
- Vol. 30 (6) , 845-851
Gut derived lactic acid bacteria induce strain specific CD4+ T cell responses in human PBMC